WP
CYTK icon

Woodline Partners’s Cytokinetics CYTK Stock Holding History

Woodline Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.8M Buy
1,100,708
+100,280
+10% +$7.2M 0.29% 77
2026
Q1 		$65.9M Sell
1,000,428
-648,000
-39% -$41.2M 0.25% 93
2025
Q4 		$105M Buy
1,648,428
+703
+0% +$43.7K 0.41% 43
2025
Q3 		$90.6M Buy
1,647,725
+1,435,422
+676% +$59.1M 0.43% 48
2025
Q2 		$7.01M Hold
212,303
– – 0.04% 499
2025
Q1 		$8.53M Buy
212,303
+86,102
+68% +$3.96M 0.06% 390
2024
Q4 		$5.94M Sell
126,201
-2,834
-2% -$147K 0.04% 453
2024
Q3 		$6.81M Sell
129,035
-69,146
-35% -$3.85M 0.06% 349
2024
Q2 		$10.7M Buy
+198,181
New +$12M 0.1% 241
2024
Q1 		– Sell
-42,652
Closed -$3.56M – 561
2023
Q4 		$3.56M Buy
+42,652
New +$1.54M 0.04% 347

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's CYTK Position: Q2 2026 in Review

Woodline Partners increased its Cytokinetics (CYTK) stake by 10% in Q2 2026, buying an estimated $7.2M and bringing the position to 1,100,708 shares worth $93.8M. The position accounts for 0.29% of the portfolio, ranked #77.

Woodline Partners first reported a position in CYTK in Q4 2023 and has held it in 10 quarters since. The position peaked at $105M in Q4 2025. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Woodline Partners held 1,100,708 shares of Cytokinetics worth $93.8M as of Q2 2026.
  • Woodline Partners bought 100,280 Cytokinetics shares in Q2 2026, an estimated $7.2M.
  • Cytokinetics made up 0.29% of Woodline Partners's portfolio in Q2 2026, its #77 holding.
  • Woodline Partners first reported a position in Cytokinetics in Q4 2023 and has held it in 10 quarters since.
  • Woodline Partners's Cytokinetics position peaked at $105M in Q4 2025.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.